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Abstract Farnesyltransferase inhibitors (FTIs) induce apopto-
sis by elevating the levels of geranylgeranylated RhoB (RhoB-
GG) in cells. However, the mechanism by which RhoB-GG acts
is unclear. Here we report that RhoB-GG is sufficient to mediate
the suppressive effects of FTIs on the activity of the survival
kinase Akt-1 in epithelial cells. This mechanism is tissue-specific
insofar as it does not operate in fibroblasts. We discuss how the
cell survival functions of RhoB and Akt may be linked
biochemically in certain cell types. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Farnesyltransferase inhibitors (FTIs) are a novel class of
cancer chemotherapeutics in human trials. The development
of FTIs was predicated on the discovery that transforming
activity of oncogenic Ras requires posttranslational isopreny-
lation [1]. Subsequent preclinical studies established biological
proof-of-principle but raised questions concerning whether
Ras alteration was important. In contrast, recent investiga-
tions have revealed a crucial role for alteration of the Rho
family protein RhoB in the FTI mechanism (reviewed in [2]).
Rho proteins regulate actin organization and cell adhesion
signaling and RhoB has a non-redundant function in intra-
cellular receptor tra⁄cking of the epidermal growth factor
(EGF) receptor [3]. FTI treatment elicits a loss of the farne-
sylated isoform of RhoB but a gain in the geranylgeranylated
isoform of RhoB (termed RhoB-GG), due to modi¢cation by
geranylgeranyl transferase-I in drug-treated cells [4]. Signi¢-
cantly, the gain of RhoB-GG is both su⁄cient and necessary
to mediate FTI response in malignant cells [5^7]. Thus, FTIs
act through a gain-of-function e¡ect related to elevation of
RhoB-GG.
How RhoB-GG signals growth inhibition and apoptosis is
unclear. In transformed ¢broblasts, the proapoptotic activity
of FTIs is not mediated by suppression of the important sur-
vival kinase Akt-1 [7^9]. However, there are reasons to think
that Akt-1 inhibition may be germane to FTI-induced apo-
ptosis by RhoB-GG in other cell types [2]. In this study, we
explored the ability of FTIs and RhoB-GG to inhibit the
activity of Akt-1 in epithelial cells. We found that Akt-1 acti-
vation by oncogenic Ras or EGF could be disrupted by FTI
treatment in COS kidney and MCF7 breast epithelial cells,
respectively. Signi¢cantly, RhoB-GG was su⁄cient to mediate
these e¡ects. The results suggested that FTIs and RhoB-GG
inhibit Akt-1 activity in epithelial cell types. A model linking
RhoB and Akt signaling is proposed. We suggest that FTIs
may have heightened clinical e⁄cacy in malignant settings
where Akt is susceptible to suppression by RhoB-GG.
2. Materials and methods
2.1. Plasmid constructions
The following expression vectors have been described: oncogenic v-
H-Ras [10]; the engineered geranylgeranylated RhoB isoforms RhoB-
GG and RhoB-V14-GG (activated by V14 mutation), and the unpre-
nylated mutant RhoB-S [5]; the dominant inhibitory RhoB mutant
RhoB-N19 [11]; the activated RhoA mutant RhoA-V14 [12]; human
Akt-1 [8]; and the p110 catalytic subunit of PI3PK [13].
2.2. Tissue culture
COS kidney cells and human MCF7 breast carcinoma cells were
obtained from ATCC and maintained in Dulbecco’s modi¢ed Eagle’s
media supplemented with 10% fetal bovine serum (Life Technologies,
Gaithersburg, MD, USA) and 50 U/ml penicillin and streptomycin
(Fisher, Pittsburgh, PA, USA). COS cells were transfected as follows:
5U105 cells were seeded in 60 mm dishes and the next day transfected
overnight with 15 Wg DNA by a modi¢ed calcium phosphate protocol
[14]. Empty vector was added where appropriate to normalize the
amount of DNA transfected. Twenty-four h after transfection, cells
were incubated in serum-free media without or with the addition of
LY 294002 for 30 min or FTI L-744,832 for 36 h at the concentrations
indicated. Cells were stimulated for 15 min with 100 ng/ml EGF (Life
Technologies) before being harvested for extract preparation, kinase
assay and Western blotting.
2.3. Retroviral-mediated gene transfer
RhoB-GG or control genes were introduced into MCF7 human
breast carcinoma cells using the murine retrovirus expression vector
MSCVpac [15]. The amphotropic packaging cell line PA317 was
transfected essentially as described [16] with 20 Wg MSCVpac vectors
using a modi¢ed calcium phosphate protocol [14]. Media supernatants
containing recombinant retroviruses were harvested 48 h after trans-
fection. Cells were refed and media harvested 8 h later and mixed with
the ¢rst round to maximize viral yield. Supernatants were clari¢ed
through a 0.45 Wm ¢lter (Millipore) and supplemented with 4 Wg/ml
polybrene (Sigma). MCF7 cells seeded in 100 mm dishes were incu-
bated with 4 ml supernatant and then supplemented after several h
with 4 ml growth media. Stably infected cell populations were selected
the next day by 72 h incubation in growth media containing 2 Wg/ml
puromycin (Sigma). Cells were then incubated overnight in media
lacking serum before stimulation for 15 min with 100 ng/ml EGF
and extract preparation.
2.4. Akt kinase assay
Cells were lysed in extraction bu¡er containing 20 mM Tris^HCl
(pH 7.5), 137 mM NaCl, 15% glycerol, 1% NP40, 2 mM PMSF, 2 Wg/
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ml aprotinin and leupeptin, 2 mM benzamidine, 20 mM sodium £uo-
ride, 10 mM sodium pyrophosphate and 1 mM sodium vanadate. Cell
lysate proteins were quantitated by Bradford assay and aliquoted for
Western analysis and Akt-1 kinase activity. in vitro kinase assays were
performed as follows. Lysates were subjected to immunoprecipitation
in NP40 bu¡er [17] with anti-HA monoclonal antibody 12CA5
(Roche Boehringer Biochemicals) or anti-Akt-1 (Santa Cruz Biotech-
nology; cat. No. sc1618) in the presence of 30 Wl protein A-Sepharose
beads for 4 h at 4‡C. The immunoprecipitate was washed once in
NP40 bu¡er and once in reaction bu¡er (below). Kinase reactions
included 10 WCi Q-32P ATP (NEN) and 4 WM unlabelled ATP in a
25 Wl reaction bu¡er composed of 20 mM HEPES (pH 7.5), 10 mM
MgCl2, 10 mM MnCl2, 1 mM DTT and 4 Wg histone H2B (Sigma) as
substrate. The reaction was incubated for 30 min at room temperature
and then fractionated by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE). Relative incorporation of radioactivity
was determined by the autoradiography of dried polyacrylamide gels.
2.5. Western analysis
Cells were washed in cold phosphate-bu¡ered saline and lysed in
1% NP40 lysis bu¡er. Cellular protein was quantitated by the Brad-
ford assay and equivalent amounts of cellular proteins were fraction-
ated by SDS^PAGE. Gels were analyzed by standard Western blot-
ting methods using 1 Wg/ml anti-HA antibody 12CA5 or anti-Akt-1
antibody. Detection of the primary antibody was carried out using an
ECM system for detection of murine antibody (Amersham).
3. Results
To determine whether FTI treatment in£uenced Akt-1 ki-
nase activity in epithelial cells, we performed a set of transient
expression assays in COS cells where Akt-1 was activated by
the co-expression of oncogenic v-H-Ras or by treatment with
EGF. Brie£y, cells were transfected with various expression
plasmids and 24 h later incubated overnight in serum-free
medium in the presence or absence of the FTI L-744,832
[18]. The Akt-1 gene product used in this study was tagged
at its N-terminus with the in£uenza virus hemagglutinin (HA)
epitope recognized by the monoclonal antibody 12CA5 [19].
Akt-1 was immunoprecipitated from cell extracts with 12CA5
and its activity was measured by an in vitro kinase assay using
histone H2B as substrate. Equal amounts of cell extract pro-
teins were subjected to Western analysis with 12CA5 to con-
¢rm that the same amount of Akt-1 was added to each kinase
reaction.
FTI was su⁄cient to inhibit Akt-1 activation by v-H-Ras in
a dose-dependent manner (see Fig. 1). Under the conditions of
the assay, v-H-Ras activated Akt-1 kinase activity several-
fold. FTI treatment reversed this e¡ect but did not suppress
kinase activity below the basal level present in the absence of
v-H-Ras (data not shown). Thus, FTI treatment inhibited
activation due to co-expression of v-H-Ras but not the intrin-
sic or background activity displayed by Akt-1 in immunopre-
cipitates from COS cells.
To determine whether RhoB-GG was su⁄cient to mediate
the e¡ect of FTIs, we performed a similar set of experiments
except that vectors expressing RhoB-GG or control genes
were co-transfected with activated v-H-Ras and Akt-1 and
the FTI treatment was omitted. In these experiments, we
also used the PI3PK inhibitor LY294002 as a positive control
for Akt-1 inhibition. As before, v-H-Ras activated Akt-1 sev-
eral-fold and treatment with 5 WM LY294002 was su⁄cient to
fully reverse this e¡ect. Similarly, cotransfection of RhoB-GG
was su⁄cient to suppress v-H-Ras-dependent activation of
Akt-1 kinase activity almost as e¡ectively as LY294002 (see
Fig. 2). This level of suppression was not accentuated by an
activated isoform of RhoB-V14-GG, suggesting that like FTI
treatment RhoB-GG suppressed activation to basal level but
not beyond. Geranylgeranylation was crucial because an un-
prenylated mutant (RhoB-S) was inactive. A dominant inhib-
itory mutant (RhoB-N19) also lacked activity, arguing that
suppression was related to GTP binding and therefore inter-
action with e¡ector molecules (rather than Rho guanine nu-
cleotide exchange factors). Lastly, the e¡ect was highly spe-
ci¢c to RhoB-GG, insofar as the closely related but di¡erently
localized RhoA protein did not a¡ect Akt-1 activation, even
when activated by mutation (RhoA-V14). Western analysis
Fig. 1. FT inhibition suppresses Akt-1 activation by oncogenic H-
Ras in COS epithelial cells. COS cells were transfected with 5 Wg of
each of the expression vectors noted. The day after transfection the
growth media was removed and replaced with media containing
0.1% fetal bovine serum. Where indicated, FTI L-744,832 was added
to cells at this time to the concentration noted. Cell extracts were
prepared and analyzed for Akt-1 expression by Western analysis
and for Akt-1 activity by in vitro kinase assay, using histone H2B
as substrate.
Fig. 2. RhoB-GG suppresses activation of Akt-1 by Ras in COS ep-
ithelial cells. Cells were transfected and processed as above except
that RhoB-GG co-expression rather than FTI treatment was tested
for inhibition of Akt-1 activity.
Fig. 3. RhoB-GG does not suppress activation of Akt-1 by PI3PK.
COS cells were transfected and processed as above except that Akt-
1 was activated by overexpression of the p110 catalytic subunit of
PI3PK.
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con¢rmed that similar amounts of Akt-1 protein were ana-
lyzed. We concluded that RhoB-GG was su⁄cient to mediate
FTI suppression of Akt-1 activation by oncogenic H-Ras.
To determine whether the suppressive e¡ects of RhoB-GG
were due to interference with Akt-1 recruitment to mem-
branes, we tested whether RhoB-GG a¡ected Akt-1 activation
by an activated isoform of the p110 catalytic subunit of PI3PK
[13]. This constitutive activity of this isoform mimicked the
constitutive activation of PI3PK that occurs in cells transfected
with v-H-Ras. As expected, Akt-1 activity was simulated sev-
eral-fold by p110. However, in this case, RhoB-GG did not
suppress Akt-1 activity, similar to the inactive mutant RhoB-S
(see Fig. 3). In contrast, cell treatment with 5 WM LY294002
fully suppressed p110-mediated activation of Akt-1. We con-
cluded that RhoB-GG suppressed activation of Akt-1 through
a mechanism(s) other than blocking its recruitment to cell
membranes.
In COS expression trials where Akt-1 was activated by 15
min treatment with 100 ng/ml EGF, instead of by co-expres-
sion of v-H-Ras, we observed that neither FTI treatment nor
ectopic RhoB-GG had any e¡ect. Treatment of COS cells
with EGF led to a several-fold activation of exogenous Akt-
1 activity, similar to v-H-Ras. However, while LY294002 in-
hibited Akt-1 activation by EGF, neither FTI nor RhoB-GG
were e¡ectual in blocking this activity (see Fig. 4A). A similar
lack of e¡ect by each was also apparent in tests where Akt-1
was stimulated by treatment with platelet-derived or insulin-
like growth factors (data not shown).
To corroborate evidence of Akt-1 suppression and address
the caveats associated with the COS transient expression as-
say, we investigated the susceptibility of endogenous Akt-1 in
MCF7 breast carcinoma cells, which respond to RhoB-GG by
apoptosis [6]. Brie£y, serum-deprived MCF7 cells were stimu-
lated as before by a 15 min treatment with 100 ng/ml EGF
following overnight treatment with FTI or transfection with
RhoB-GG or control vectors. Extracts were prepared in a
similar manner to COS cells and processed by in vitro kinase
assay as before. We observed stimulation of endogenous Akt-
1 activity by EGF and suppression by FTI or RhoB-GG but
not the inactive RhoB-S mutant (see Fig. 4B). Panc-1 human
pancreatic carcinoma cells have been reported to be suscepti-
ble to FTI-induced apoptosis [20], and we observed similar
suppression of EGF-stimulated Akt-1 activity by RhoB-GG
in Panc-1 cells (data not shown). We concluded that RhoB-
GG was su⁄cient to mediate suppression of Akt-1 when ac-
tivated by EGF in human cells.
4. Discussion
This study de¢nes a mechanism through which FTI can
inhibit activation of the survival kinase Akt-1 in epithelial
cells. This mechanism is tissue-speci¢c insofar as it does not
operate in transformed ¢broblasts [7^9]. RhoB-GG is su⁄-
cient to mediate apoptosis by FTI treatment in MCF7 carci-
noma cells [6]. The ¢ndings of this study establish that RhoB-
GG is also su⁄cient to mediate Akt-1 suppression by FTI.
Our results are consistent with a report that FTI treatment
can suppress activation of the related Akt-2 kinase in ovarian
and pancreatic carcinomas [20]. The ability of RhoB-GG to
mediate FTI e¡ects suggests how FTI may a¡ect Akt-2 in
these epithelial tumor cell types.
We observed di¡erential susceptibility of Akt-1 in COS cells
when Akt-1 was activated by oncogenic Ras versus EGF
treatment. This di¡erence did not re£ect a de¢cit in the ability
to block Akt-1 when it is stimulated by EGF, because both
FTI and RhoB-GG could suppress EGF-stimulated activation
of Akt-1 in MCF7 or Panc1 carcinoma cells. Thus, it seems
likely that a variation in the con¢guration of Akt signaling
Fig. 4. FTI or RhoB-GG suppress activation of endogenous Akt-1 by EGF in MCF7 carcinoma cells. Cells were infected with amphotropic
retroviral vectors as noted in Section 2 and processed as above for Akt-1 kinase activity and Western analysis. Brie£y, cells were deprived of
serum and treated where indicated with 10 WM L-744,832. Twenty-four h later cells were harvested or stimulated for 15 min with 100 ng/ml
EGF before harvest. A: FTI and RhoB-GG do not a¡ect activation of Akt-1 by EGF in transiently transfected COS cells. B: RhoB-GG is
su⁄cient to mediate FTI suppression of endogenous Akt-1 when the latter is activated by EGF in MCF7 breast carcinoma cells.
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pathways regulated by EGF in COS and MCF7 cells accounts
for the di¡erence in RhoB-GG susceptibility. This variation
may be useful to pinpoint the mechanism by which RhoB-GG
regulates Akt-1 activity. One question is whether isoprenyla-
tion type in£uences the ability to suppress Akt-1 activity.
Farnesylated RhoB is eliminated by FTI treatment and there-
fore not a player in the FTI response. However, it would be of
interest to compare the e¡ects of isoprenylation on Akt-1
activity using a RhoB mutant made recently that is strictly
farnesylated in cells [21].
Akt-1 is activated in several steps, the ¢rst of which does
not appear to be a¡ected by RhoB-GG. Recruitment of PI3PK
to activated receptors leads to an increase in the level of phos-
phatidylinositol 3,4-phosphate in membranes, causing recruit-
ment of proteins such as Akt-1 and Pdk1 that contain Pleck-
strin homology (PH) domains, which bind to the bisphosphate
inositol headgroup on the lipid. This step was not susceptible
to RhoB-GG inhibition, insofar as RhoB-GG was unable to
block Akt-1 activation by a constitutively activated isoform of
the p110 catalytic subunit of PI3PK. The second step in Akt-1
activation is phosphorylation by Pdk1, and possibly other
kinases, which are stimulated by upstream signals that are
largely uncharacterized. Later steps in Akt-1 activation in-
volve additional protein^protein interactions and nuclear
translocation [22,23]. By inference RhoB-GG must act at
one or more of these steps. For proper tra⁄cking of the
EGF receptor RhoB must recruit Prk to early endosomal
membranes [3,24]. Interestingly, Prk was recently reported
to associate with and regulate the substrate speci¢city of
Pdk1, promoting the latter to phosphorylate the so-called
Pdk2 activation site (S473) on Akt-1 [25]. RhoB-GG does
not localize to the appropriate endosomal compartment in
FTI-treated cells [26], so one possibility is that RhoB-GG
in£uence Akt activation by a¡ecting Prk-dependent control
of Pdk1 localization and/or activity [2].
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